BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 20071495)

  • 1. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin: first-in-class macrocyclic antibiotic.
    Mullane KM; Gorbach S
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):767-77. PubMed ID: 21810048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
    Louie TJ; Emery J; Krulicki W; Byrne B; Mah M
    Antimicrob Agents Chemother; 2009 Jan; 53(1):261-3. PubMed ID: 18955523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
    Louie T; Miller M; Donskey C; Mullane K; Goldstein EJ
    Antimicrob Agents Chemother; 2009 Jan; 53(1):223-8. PubMed ID: 18955525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
    Zhanel GG; Walkty AJ; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2015; 26(6):305-12. PubMed ID: 26744587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative therapies for Clostridium difficile infections.
    Venuto C; Butler M; Ashley ED; Brown J
    Pharmacotherapy; 2010 Dec; 30(12):1266-78. PubMed ID: 21114394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of OPT-80 against Clostridium difficile.
    Ackermann G; Löffler B; Adler D; Rodloff AC
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2280-2. PubMed ID: 15155234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
    Morrow T
    Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.